Product information and disease descriptionPlace of product in therapyDisease description
Definition and etiology
11 evidence topics · 7 sources
Hormone receptor-positive and HER2-positive tumor definitions
Estrogen receptor-positive threshold: ASCO/CAP guideline
“Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HER2 status: ASCO/CAP guideline
“The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intrinsic subtypes and their hormone receptor surrogates
Advanced breast cancer: international consensus definition
“In the ABC guidelines, advanced breast cancer is defined as comprising both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC), which includes both distant recurrent disease and stage IV at diagnosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Advanced/metastatic breast cancer is still an incurable disease for the vast majority of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distant stage and stage IV classification
De novo and recurrent metastatic disease
“Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Previously treated disease: endocrine resistance definitions
“Primary endocrine resistance is defined as relapse while on the first two years of adjuvant endocrine therapy for early breast cancer, or progressive disease within the first six months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary or acquired endocrine resistance encompasses all remaining clinical situations of endocrine resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first subgroup, early acquired endocrine resistance , includes relapse while receiving endocrine therapy but after the first two years, relapse within one year of completing adjuvant endocrine therapy, or progressive disease occurring after at least six months, but less than twelve months, of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second subgroup, late acquired endocrine resistance , is defined as relapse more than twelve months after completing adjuvant endocrine therapy, or progressive disease after at least twelve months of first line endocrine therapy-based treatment for advanced breast cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote